Kura Oncology, Inc. $KURA Shares Sold by Alethea Capital Management LLC

Alethea Capital Management LLC lessened its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 7.5% in the 4th quarter, Holdings Channel reports. The firm owned 1,422,682 shares of the company’s stock after selling 116,112 shares during the period. Kura Oncology accounts for 7.2% of Alethea Capital Management LLC’s investment portfolio, making the stock its 4th largest holding. Alethea Capital Management LLC’s holdings in Kura Oncology were worth $14,782,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of KURA. IFP Advisors Inc raised its position in shares of Kura Oncology by 115.3% during the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after purchasing an additional 1,284 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Kura Oncology by 392.8% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after purchasing an additional 3,072 shares during the last quarter. Allworth Financial LP raised its position in shares of Kura Oncology by 59.9% during the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after purchasing an additional 1,553 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Kura Oncology by 127.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after purchasing an additional 3,769 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Kura Oncology by 471.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after purchasing an additional 9,958 shares during the last quarter.

Kura Oncology Stock Down 2.1%

Shares of NASDAQ:KURA opened at $8.56 on Tuesday. The business has a 50-day moving average price of $9.24 and a 200 day moving average price of $9.38. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $759.87 million, a price-to-earnings ratio of -2.56 and a beta of 0.36. Kura Oncology, Inc. has a 12-month low of $5.45 and a 12-month high of $12.49.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.05. The firm had revenue of $18.27 million during the quarter, compared to the consensus estimate of $25.97 million. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%. Sell-side analysts expect that Kura Oncology, Inc. will post -3.47 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a research note on Thursday, May 28th. Oppenheimer set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, May 28th. Wedbush dropped their price target on shares of Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, March 6th. Lake Street Capital started coverage on Kura Oncology in a research report on Tuesday, April 14th. They issued a “buy” rating and a $23.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research report on Tuesday, April 21st. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $25.58.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.